has a potential effect on some of the elements that comprise the composite outcome (eg, cerebrovascular events) is plausible, and has to be studied and validated in future studies. The effect of CPAP on specific modalities of coronary artery disease and patients with daytime sleepiness deserve to be studied in future randomised controlled trials. However, in general, patients with acute coronary syndrome are not sleepy and the number of patients excluded from our study because of excessive daytime sleepiness was very low.
It would be convenient to propose an approach, following the principles of precision medicine, that would allow the identification of the specific phenotype of patients who would benefit from CPAP treatment and enable a concrete outcome to be defined. Moreover, it could be hypothesised that OSA could induce deleterious effects that might increase the risk of event recurrence in patients with low comorbidity who had a major cardiovascular event. No potential beneficial effects of OSA treatment would be expected if a clear increase in the risk of recurrence in patients with OSA was not previously observed with respect to patients without OSA.
The possible positive effect of CPAP treatment on specific outcomes or particular phenotypes of patients with
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The results of the ISAACC study, and those of the SAVE 2 and RICCADSA 3 trials, have not shown a beneficial effect of continuous positive airway pressure (CPAP) treatment in secondary cardiovascular prevention. This neutral effect is not surprising because, as shown in figure 2 of the Article, obstructive sleep apnoea (OSA) does not increase the risk of the incidence of cardiovascular events. A considerable number of the patients with OSA in our study had a notable comorbid condition, which might have exerted a ceiling effect on how much OSA could increase the risk of recurrence of cardiovascular events.
Although patients from the RICCADSA study, who reported higher CPAP use than in the SAVE or ISAACC study, showed a reduction in a composite cardiovascular outcome, this reduction was not observed in the larger SAVE and ISAACC studies. The hypothesis that CPAP treatment OSA should be explored and shown in future studies.
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